Korea adds Pergoveris pen to reimbursement rolls, vial already covered
This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
Access Read
CDA-AMC reverses course, backs Leqembi’s first ruling content still undisclosed
Four words carry the news: follows a reconsideration. CDA-AMC reached a different conclusion first, and neither release says what it was.
Nine More Drugmakers Signed MFN Deals. The Coalition Formed to Fight Them Did Not.
The useful information is who is absent. The mid-sized biotech coalition formed to contest MFN has no member among the nine signatories.
Korea Runs Three Reimbursement Speeds. September Shows All Three at Once.
The lane determines the timeline, and it is set long before you file. Model the Korean queue, not the approval date.
Abbott Cleared the First Dual Glucose and Ketone Sensor. FDA Judged Accuracy, Not Admissions.
The label says diabetes. The clinical argument is type 1. Coverage conversations start from 2.1 million people, not 40.1 million.
This Money Buys Equipment, Not Operations. Your 2031 Answer Decides the 2027 Deal.
Half the pot is split equally, so award size is a weak proxy for market size. Your buyer is a state rural health office, not a hospital.
Evernorth Adopts LOCUS in Three States, and States That the Review Process Is Not Changing
Three statutes across five years, discharged on one date. Evernorth says only the source of criteria changes, not the review process itself.
DOJ Settled With the In-Home Vendor, Not the Health Plan, Over Four Medicare Advantage Codes
DOJ did not settle with a health plan. It settled with the in-home vendor that supplied the codes, and named the risk-share contract as the incentive.
China Will Pay One Price for 158 Conditions, Whatever the Hospital
Same disease, same payment across tiers. Of 31 DRG categories, 27 are internal medicine, where drug cost rather than theatre time drives the case.
France Funded Two Cancer Drugs the Same Week. One Was Rated Therapeutic Progress, One Was Not.
Listing is granted by indication, not by licence. Columvi is funded for one situation and refused for the rest of its authorisation.